Uwe Gottschalk appointed as Board Observer

We are excited to announce the appointment of Dr. Uwe Gottschalk as Board Observer.

Uwe Gottschalk, presently an Operating Partner at Keensight Capital, will participate as an Observer in the Board of Directors and Steering Committee Meetings, bringing extensive expertise, vision and international contacts.

Welcome aboard Uwe!

About Uwe Gottschalk

Uwe Gottschalk is Operating Partner at Keensight Capital, a European Growth Buyout Investor with deep expertise in Technology and Healthcare. Before joining Keensight Capital in 2022 he was Chief Technology Officer (2014-2017) and Chief Scientific Officer (2017-2021) at Lonza where he established and led the global Research and Technology organisation.

Uwe served as Group Vice President at Sartorius Stedim Biotech between 2004 and 2014 with a global responsibility for all bioseparation-related process technology. He worked in different capacities for Bayer Health Care from 1991 to 2004, overseeing the process development and manufacturing of biopharmaceutical products such as monoclonal antibodies and other recombinant proteins.

Uwe earned his M.Sc and PhD in Chemistry at the University of Münster, Germany and Nottingham, UK, delivering his dissertation on drug targeting with monoclonal antibodies. He has written extensively in the areas of downstream processing, industrial biotechnology and somatic gene therapy. In academia, Dr. Gottschalk was Head Lecturer at the University of Duisburg-Essen (Germany) and also lectured at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Lausanne (Switzerland).

Uwe was a board member of the VBU Association of German Biotech Companies between 2006 and 2010. He sits on the editorial advisory boards of Pharmaceutical Bioprocessing, Genetic Engineering News and BioPharm International. He is honorary member of the Society for BioChromatography and Nanoseparations, member of the Management Pool at the Institut of Marketing, University of St. Gallen (HSG) and member of the American Chemical Society (ACS). In 2021 he received the Bioprocessing Lifetime Achievement Award at the Asia Biologics Manufacturing Conference.

Uwe Gottschalk is a Board Member at Biovian – an end-to-end biopharmaceutical CDMO – and acts as a Board Observer at Axxam – an innovative CRO that identifies and validates bioactive molecules across all life sciences industries.

Scroll to Top